Akums Drugs and Pharmaceuticals Limited IPO: A Comprehensive Analysis

Timeline

IPO Open Date:	July 30, 2024
IPO Close Date:	August 1, 2024
Basis of Allotment:	August 2, 2024
Refunds:	August 5, 2024
Credit to Demat Account:	August 5, 2024
IPO Listing Date:	August 6, 2024

About Company

Akums Drugs and Pharmaceuticals Limited is a prominent player in the Indian pharmaceutical landscape, specializing in the contract development and manufacturing organization (CDMO) model. Established in 2004, the company has grown significantly to offer a comprehensive range of pharmaceutical products and services.

Core Business:

• Contract Development and Manufacturing Organization (CDMO): Akums provides end-to-end solutions for product development, manufacturing, and research and development (R&D) of formulations, preparations, and active pharmaceutical ingredients (APIs).
• Product Range: Their portfolio encompasses a wide range of pharmaceutical products, including anti-infectives, analgesics, anti-malarials, and anti-allergics.

Market Presence:

• Akums has a substantial presence in both domestic and international markets.
• The company boasts a strong distribution network to ensure wide reach and accessibility for its products.

Focus on Quality and Compliance:

• Akums is committed to maintaining stringent quality standards and regulatory compliance. Their manufacturing facilities adhere to global benchmarks like WHO-GMP, US FDA, and UK MHRA.

Future Outlook:

• Akums is poised to benefit from the growing Indian pharmaceutical market and the increasing demand for contract manufacturing services.
• Their focus on R&D and product development suggests a strategic approach to stay competitive and expand their product portfolio.

Key Points to Remember:

• Akums is a significant player in the Indian pharmaceutical industry.
• Their CDMO model offers a comprehensive range of services.
• The company has a global presence and a focus on quality and compliance.

Here are some resources to learn more about company

• Company Website: https://www.akums.in/

---

Objective

The Company proposes to utilise the Net Proceeds towards funding the following objects:

• Repayment/ prepayment of indebtedness of the company and its Subsidiaries;
• Funding incremental working capital requirements of the company;
• Pursuing inorganic growth

POSITIVE

• Strong presence in both domestic and international markets
• Diversified product portfolio with a focus on high-growth segments
• Robust R&D capabilities and a commitment to innovation
• Experienced management team with a proven track record

NEGATIVE

• Intense competition in the pharmaceutical industry
• Regulatory challenges and pricing pressures
• Dependence on a few key products and customers
• Global economic uncertainties and geopolitical risks

So,How Does Akums Drugs and Pharmaceuticals Limited IPO Fare in Terms of Financials ?

Financial Details

Period Ended	31 Mar 2024	31 Mar 2023	31 Mar 2022
Assets	3,516.37	3,266.53	3,069.05
Revenue	4,212.21	3,700.93	3,694.52
Profit After Tax	0.79	97.82	-250.87
Net Worth	709.50	717.19	621.98
Reserves and Surplus	861.01	868.70	787.79
Total Borrowing	491.56	536.97	357.95
Amount in ₹ Crore

Akums Drugs and Pharmaceuticals Limited IPO Valuation :

KPI	Values
ROE	0.11%
ROCE	3.37%
Debt/Equity	0.69
RoNW	-0.57
P/BV	13.69
PAT Margin (%)	0.02

Akums Drugs and Pharmaceuticals Limited IPO – SWOT Analysis

Strengths

• Strong brand recognition and reputation
• Diversified product portfolio and presence in high-growth segments
• Robust R&D capabilities and innovation pipeline

Weaknesses

• Dependence on a few key products and customers
• Limited global presence compared to peers
• Regulatory challenges and pricing pressures

Opportunities

• Growing demand for pharmaceuticals in India and globally
• Increasing focus on healthcare and wellness
• Expansion into new markets and segments

Threats

• Intense competition and pricing pressures
• Regulatory challenges and changes in government policies
• Global economic uncertainties and geopolitical risks

COMPETITIVE ANALYSIS: MARKET PEERS

• Sun Pharmaceutical Industries Limited
• Cipla Limited
• Lupin Limited
• Dr. Reddy’s Laboratories Limited
• Aurobindo Pharma Limited

Akums Drugs and Pharmaceuticals Limited IPO GMP

• Grey market premium as on DD-MM-YYYY = Rs / Share

Disclaimer:

• IPO Grey Market Premium (Akums Drugs and Pharmaceuticals Limited IPO GMP) mention is valid for the specific date as mentioned in the header.
• We are not buying and selling IPO forms on IPO Grey Market.
• Don’t decide to subscribe to an IPO just based on the initial price, as it can change before the listing.Subscribe only considering Fundamentals of the companies.

Akums Drugs and Pharmaceuticals Limited IPO

🔴 Live Subscription Status 🔴

30/07/2024 10:00 AM

	NO OF SHARES OFFERED	Day 1	Day 2	Day 3
Qualified Institutional Buyers(QIBs)
Non Institutional Investors(NIIs)
Retail Individual Investors(RIIs)
Employee
Total

FINAL TAKEAWAY

✅ May Apply

HOW APPLY IPO USING DEMAT , UPI, ASBA, NET BANKING ETC ?

These are simple and effective steps that increase your IPO allotment chances. Check our page on how to improve IPO allotment chances.

Happy investing!🤩